Improve contrast of 120 kVp single-energy body CT images by estimating 50 keV GSI-like images as non-quantitative adjunct information for patients of all ages; the original 120 kVp image must remain available for interpretation.
Clinical role
Post-processing and reconstruction contrast-enhancement option within Revolution Ascend; the user selects a phase model and compares the adjunct output with the original 120 kVp image.
Images and patients
CT/CTA · Body
Key limitation
Only 120 kVp acquisitions on non-GSI Revolution Ascend systems are covered. The output is not quantitative, must not be interpreted without the original 120 kVp image, and is not intended to replace hardware-based GSI or replicate dual-energy acquisition. The FDA indication allows patients of all ages but does not establish a broader modality or system scope.
Overview status: Field-derived fact summary This section is assembled from the sourced field records below; it is not a source-reviewed editorial overview.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Imaging and anatomyCT/CTA · Body
Workflow rolePost-processing and reconstruction contrast-enhancement option within Revolution Ascend; the user selects a phase model and compares the adjunct output with the original 120 kVp image.
Required input120 kVp single-energy, non-GSI body CT images acquired on Revolution Ascend Elite, Plus, or Select systems, using Standard, Soft, or Detail reconstruction kernels; the packet states that the input acquisition parameters are not changed.
Output and human actionNon-quantitative contrast-enhanced images estimating monochromatic 50 keV GSI images, with better contrast than the single-energy input; four models are available for CT angiography, arterial, portal/venous, and delayed phases.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Improve contrast of 120 kVp single-energy body CT images by estimating 50 keV GSI-like images as non-quantitative adjunct information for patients of all ages; the original 120 kVp image must remain available for interpretation.
Exact FDA submission
Checked 2026-09-19
Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.
Post-processing and reconstruction contrast-enhancement option within Revolution Ascend; the user selects a phase model and compares the adjunct output with the original 120 kVp image.
120 kVp single-energy, non-GSI body CT images acquired on Revolution Ascend Elite, Plus, or Select systems, using Standard, Soft, or Detail reconstruction kernels; the packet states that the input acquisition parameters are not changed.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Non-quantitative contrast-enhanced images estimating monochromatic 50 keV GSI images, with better contrast than the single-energy input; four models are available for CT angiography, arterial, portal/venous, and delayed phases.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Only 120 kVp acquisitions on non-GSI Revolution Ascend systems are covered. The output is not quantitative, must not be interpreted without the original 120 kVp image, and is not intended to replace hardware-based GSI or replicate dual-energy acquisition. The FDA indication allows patients of all ages but does not establish a broader modality or system scope.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
FDA K233698 reports design verification, phantom and image-quality testing using IEC 61223-3-5-related metrics, a retrospective reader study in which four board-certified radiologists compared diagnostic-use image quality and contrast, and material comparisons with 50 keV and 120 kVp reference images. The reviewed FDA text reports qualitative image-quality and contrast validation but no sample size or numerical clinical diagnostic-performance metrics.
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K233698 reports design verification, phantom and image-quality testing using IEC 61223-3-5-related metrics, a retrospective reader study in which four board-certified radiologists compared diagnostic-use image quality and contrast, and material comparisons with 50 keV and 120 kVp reference images. The reviewed FDA text reports qualitative image-quality and contrast validation but no sample size or numerical clinical diagnostic-performance metrics.
FDA source
Exact FDA submission
Checked 2026-09-19
Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
True Enhance DL regulatory performance study summary
DesignReader Study
PopulationAdult and Pediatric
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K233698
IndependenceIndependence not established
K233698
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K233698. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: 120 kVp single-energy, non-GSI body CT images acquired on Revolution Ascend Elite, Plus, or Select systems, using Standard, Soft, or Detail reconstruction kernels; the packet states that the input acquisition parameters are not changed.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: The option is deployed within Revolution Ascend acquisition and processing software on the same hardware and software platform. The packet does not establish DICOM, PACS, RIS, EHR, external interface, or standalone deployment details.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Non-quantitative contrast-enhanced images estimating monochromatic 50 keV GSI images, with better contrast than the single-energy input; four models are available for CT angiography, arterial, portal/venous, and delayed phases.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Non-quantitative contrast-enhanced images estimating monochromatic 50 keV GSI images, with better contrast than the single-energy input; four models are available for CT angiography, arterial, portal/venous, and delayed phases.
Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
The option is deployed within Revolution Ascend acquisition and processing software on the same hardware and software platform. The packet does not establish DICOM, PACS, RIS, EHR, external interface, or standalone deployment details.
GE HealthCare's Product Security Portal is described as a credentialed global portal giving customers security updates, vulnerability status and required actions for GE HealthCare products potentially impacted by critical vulnerabilities, plus historical patch views; GE HealthCare references its Cybersecurity Risk Management System and publishes a Coordinated Vulnerability Disclosure Statement for reporting vulnerabilities in GE HealthCare products.
Vendor-wide
Checked 2026-10-26
Vendor statement, not an attestation. Identity bridge: GE HealthCare's own offices page on gehealthcare.com names GE HealthCare Japan Corporation. Corporate program statement; portal content is credentialed; exact-release scope is not established.
GE HealthCare's product security page states that it provides a credentialed Product Security Portal offering security updates, vulnerability status and actions, and patch views for GE HealthCare products under its Cybersecurity Risk Management System, and links its Coordinated Vulnerability Disclosure Statement.
Vendor-wide
Checked 2026-10-27
Vendor statement, not an attestation. The page names GE HealthCare generally and does not scope these commitments to any specific product release; exact-release scope is not established. Portal access is credentialed; contents were not read.
ACR AI Central provides an exact-submission model card for True Enhance DL; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-19Last searched
21Fields reviewed
10Source classes checked
0Awaiting review PubMed leads
0Awaiting review trial leads
0Unreviewed FDA recall leads
Exact-submission ACR model-card fields were normalized under the current provenance rules; vendor and independent-study confirmation remain distinct. Exact FDA packet assessed on 2026-09-19. Directory-backed facts were reconciled only where purpose, modality, and anatomy were each directly established. Candidate literature and postmarket candidates remain in their existing review state. Automated exact-name discovery found 0 PubMed and 0 ClinicalTrials.gov candidate records. Candidates require human product and version matching; zero candidates is not evidence that no studies exist. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads remain unpublished until a human confirms the exact product and tested version.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, fda decision summary packet, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Intended users: Withdrawn - checked 2026-09-19 - Exact FDA submission
Previous value withdrawn: The exact FDA decision-summary packet reviewed on 2026-09-19 does not establish this claim.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K233698 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Authorized purpose: Auto-Seg and Spine Auto-Seg accept spine and pelvis CT images and provide three-dimensional segmentation and labels to support spine-surgery planning and assessment by spine surgeons.
Authorized purpose: Acorn 3D Software and Acorn 3DP Model process CT, synthetic CT, and CT angiography for segmentation, visualization, measurement, treatment planning, and three-dimensional printing, including adult and pediatric spine trajectory planning.
Modality
CT/CTA
Anatomy
Spine; craniomaxillofacial; musculoskeletal anatomy; and patient-specific printed models
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.